文摘
摘要目的:比较生殖之间的历史特征的女性多发性硬化症(MS)和控制女性。
背景:生殖周期从月经初潮自然绝经常常标志着活跃的炎性疾病时期女士之间的关系性荷尔蒙和免疫系统可能在疾病过程中起着重要的作用在女性的女士。
设计/方法:病例对照研究的女性和年龄女士控制女性以人群为基础的队列。月经初潮年龄,足月怀孕和不完整的,更年期绝经年龄和类型比较在137年与MS和396匹配控制女性绝经后妇女。
结果:在女性月经初潮年龄相似女士和控制女性(中位数、四分位范围(差);女士13年12 - 13.2;控制12年,12 - 13;p = 0.306)。较低数量的女士怀孕的女性比控制女性(中位数,差;女士2、1 - 3;控制3、2 - 4;p = 0.001)和足月怀孕数量低于控制女性(平均差;女士2、1 - 3;控制3 2 - 3; p<0.001). Age at menopause was not different between MS and controls (median, IQR; MS 49 years, 44.5–52; controls 50 years, 43–52; p=0.791). Age at natural menopause was similar between MS and controls as well (median, IQR; MS 50 years, 48–52; controls 51 years, 49–53; p=0.476). Non-natural menopause was more frequent in women with MS (40.7%) compared to control women (30.1%) (p=0.030).
结论:自然生殖的里程碑,初潮的年龄和年龄自然更年期,女性没有差异女士和控制。自然绝经年龄是类似于先前的研究在女士和51在西方人群的平均年龄。总的来说,女士似乎并不直接影响女性的自然生殖的里程碑。然而,除了手术绝经期,免疫调节可能与更高的频率相关的非天然的更年期。
披露:Zeydan博士的机构已经收到了来自美国国立卫生研究院的研究支持。伊丽莎白·阿特金森没有披露。Delana Weis没有披露。Carin史密斯没有披露。直系亲属成员机构的莉莉安娜Gazzoula罗卡已收到国家老化研究所- NIH的研究支持。直系亲属成员机构的莉莉安娜Gazzoula罗卡已经收到国家心脏研究支持,肺和血液研究所——国家卫生研究院。罗卡博士的机构已收到国家老化研究所- NIH的研究支持。罗卡已收到博士研究的机构支持国家心脏,肺和血液研究所,国家卫生研究院。基冈博士已经收到相关出版物的出版版税卫生保健。Weinshenker博士已经收到个人薪酬在500 - 4999美元的范围为三菱田边担任顾问。 Dr. Weinshenker has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Weinshenker has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Viela Bio. Dr. Weinshenker has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche Group (Chugai, Genentech, Roche). The institution of Dr. Weinshenker has received research support from Guthy Jackson Charitable Foundation. Dr. Weinshenker has received intellectual property interests from a discovery or technology relating to health care. Dr. Weinshenker has received personal compensation in the range of $500-$4,999 for serving as a speaker at internal meeting with Genentech. The institution of Dr. Kantarci has received research support from Eli Lilly. The institution of Dr. Kantarci has received research support from NIH. The institution of Dr. Kantarci has received research support from ADDF. Dr. Kantarci has nothing to disclose.
